Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.37 |
| ▸ | CFD | P00746 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26599004 | 0.89 | CFD (0.40) | ALDH1A1KMT2ACFD | |
| SCHEMBL30606567 | 0.89 | CFD (0.40) | ALDH1A1KMT2ACFD | |
| SCHEMBL26599214 | 0.86 | GAA (0.49) | OPRL1POLBMEN1KMT2ACFD | |
| SCHEMBL30606572 | 0.86 | GAA (0.49) | OPRL1POLBMEN1KMT2ACFD | |
| SCHEMBL1197654 | 0.84 | CASR (0.36) | ALDH1A1POLBMEN1KMT2ACASR | |
| SCHEMBL19234629 | 0.79 | OPRM1 (0.36) | OPRL1CFDCASR | |
| SCHEMBL1196651 | 0.74 | POLB (0.50) | ALDH1A1OPRL1POLBKMT2ASSTR4 | |
| SCHEMBL8263707 | 0.73 | L3MBTL1 (0.49) | OPRL1KMT2A | |
| SCHEMBL5987343 | 0.72 | GAA (0.46) | ALDH1A1OPRL1POLBMEN1KMT2A | |
| SCHEMBL4220278 | 0.72 | GAA (0.46) | OPRL1KMT2ASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663971-B1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-10 | — | — | US | disclosed |
| US-7803813-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-7291632-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060287363-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists | ELLI LILLY AND COMPANY (US) | 2006-12-21 | — | — | US | disclosed |
| EP-1663971-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | Eli Lilly and Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005035499-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287363-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists | HTR1F, HTR1A, HTR3B | ALDH1A1 1980/4885OPRL1 25/4885POLB 3784/4885 |
| US-20110034511-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | HTR1F, HTR1A, HTR3B | ALDH1A1 2051/4885OPRL1 24/4885POLB 3309/4885 |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | HTR1F, HTR1A, HTR3B | ALDH1A1 2051/4885OPRL1 24/4885POLB 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.